Cingulate Inc.
CTx-1301
ADHD
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews CTx-1301 for ADHD around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Cingulate is actively collaborating with the FDA to provide responses to information requests related to the manufacturing and CMC elements of its CTx-1301 NDA.”